Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
320 West 37 Th Street, New York, NY
State of incorporation
Delaware
Fiscal year end
March 31
Former names
Health Sciences Acquisitions Corp (to 12/20/2019)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.36K % +39.5%
Debt-to-equity 7.93 % -30.7%
Return On Equity -52.1 % +21.6%
Return On Assets -48.3 % +19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 146M shares +12%
Common Stock, Shares, Outstanding 146M shares +12%
Entity Public Float 2.18B USD +811%
Common Stock, Value, Issued 14K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 146M shares +11.9%
Weighted Average Number of Shares Outstanding, Diluted 146M shares +11.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 128M USD +60.3%
General and Administrative Expense 60.7M USD +17.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -272M USD -11%
Income Tax Expense (Benefit) 655K USD
Net Income (Loss) Attributable to Parent -273M USD -11.5%
Earnings Per Share, Basic -1.91 USD/shares +1.04%
Earnings Per Share, Diluted -1.91 USD/shares +1.04%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 560M USD +69.7%
Accounts Receivable, after Allowance for Credit Loss, Current 2.42M USD +194%
Assets, Current 589M USD +68.3%
Property, Plant and Equipment, Net 565K USD +73.8%
Operating Lease, Right-of-Use Asset 66K USD -92.5%
Assets 590M USD +67.9%
Accounts Payable, Current 11M USD -58.3%
Accrued Liabilities, Current 33.9M USD +41.4%
Liabilities, Current 45M USD -12.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 45M USD -12.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.82M USD +213%
Retained Earnings (Accumulated Deficit) -913M USD -42.6%
Stockholders' Equity Attributable to Parent 545M USD +81.6%
Liabilities and Equity 590M USD +67.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -76.2M USD -60.9%
Net Cash Provided by (Used in) Financing Activities 686K USD -22.9%
Net Cash Provided by (Used in) Investing Activities -182K USD -304%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 146M shares +12%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -75.4M USD -61.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 560M USD +69.7%
Deferred Tax Assets, Valuation Allowance 141M USD +53.8%
Deferred Tax Assets, Gross 142M USD +53.3%
Operating Lease, Liability 138K USD -88.7%
Depreciation 80K USD +50.9%
Payments to Acquire Property, Plant, and Equipment 182K USD +304%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -272M USD -11.8%
Lessee, Operating Lease, Liability, to be Paid 141K USD -88.7%
Operating Lease, Liability, Current 69K USD -92.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 47K USD -96.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 141K USD -88.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -88%
Lessee, Operating Lease, Liability, to be Paid, Year Three 47K USD -95.8%
Deferred Tax Assets, Operating Loss Carryforwards 98.2M USD +52.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 1.46B USD +54.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 347K USD -30.9%
Share-based Payment Arrangement, Expense 43.8M USD +24.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%